Celebrating 25 years Est 1999-2024
*Across 3 years $2276.64 only $1138.32
FORM 4 ☒ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 ...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EFFECTIVENESSEffective Date:December 05, 2022...
As filed with the Securities and Exchange Commission on December 1, 2022 Registration No. 333-263837 Registration No. 333-261054...
As filed with the Securities and Exchange Commission on December 1, 2022. Registration No. 333-236977 Registration No. 333-260299...
UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER...
Robert W. Baird analyst Jack Allen maintained a Hold rating on Renovacor (RCOR - Research Report) on November 14 and set a price target of $2.75...
Filed Pursuant to Rule 424(b)(3) Registration No. 333-260299 Prospectus Supplement No. 13...
falsethree years--12-31Q300017998500001799850us-gaap:MeasurementInputSharePriceMemberrcor:PrivatePlacementWarr...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K ...
false 0001799850 0001799850 2022-10-14 2022-10-14 0001799850 rcor:CommonStockParValue0.0001PerShare2Member 2022-10-14 2022-10-14 0001799850...
Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.